As on January 06, 2021, Intra-Cellular Therapies Inc. (NASDAQ: ITCI) got off with the flyer as it spiked 3.43% to $32.86. During the day, the stock rose to $33.625 and sunk to $31.70 before settling in for the price of $31.77 at the close. Taking a more long-term approach, ITCI posted a 52-week range of $10.94-$33.74.
Meanwhile, its Annual Earning per share during the time was -20.10%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 5.60%. This publicly-traded company’s shares outstanding now amounts to $80.16 million, simultaneously with a float of $72.05 million. The organization now has a market capitalization sitting at $2.67 billion. At the time of writing, stock’s 50-day Moving Average stood at $26.72, while the 200-day Moving Average is $23.03.
While finding the extent of efficiency of the company that is accounted for 330 employees. It has generated 184 per worker during the last fiscal year. For the Profitability, stocks operating margin was -254090.46 and Pretax Margin of -243711.05.
Intra-Cellular Therapies Inc. (ITCI) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Intra-Cellular Therapies Inc.’s current insider ownership accounts for 3.40%, in contrast to 86.30% institutional ownership. According to the most recent insider trade that took place on Jan 04, this organization’s SVP of Finance CFO sold 15,810 shares at the rate of 31.31, making the entire transaction reach 495,008 in total value, affecting insider ownership by 350. Preceding that transaction, on Jan 04, Company’s EVP and General Counsel sold 16,160 for 31.30, making the whole transaction’s value amount to 505,834. This particular insider is now the holder of 0 in total.
Intra-Cellular Therapies Inc. (ITCI) Earnings and Revenue Records
If we go through the results of last quarter, which was made public on 9/29/2020, the company posted -$0.79 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -$1) by $0.21. This company achieved a net margin of -243713.69 while generating a return on equity of -57.62. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.88 per share during the current fiscal year.
Intra-Cellular Therapies Inc.’s EPS increase for this current 12-month fiscal period is 5.60% and is forecasted to reach -3.02 in the upcoming year.
Intra-Cellular Therapies Inc. (NASDAQ: ITCI) Trading Performance Indicators
Let’s observe the current performance indicators for Intra-Cellular Therapies Inc. (ITCI). It’s Quick Ratio in the last reported quarter now stands at 19.50. The Stock has managed to achieve an average true range (ATR) of 1.33. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 256.62.
In the same vein, ITCI’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.22, a figure that is expected to reach -0.88 in the next quarter, and analysts are predicting that it will be -3.02 at the market close of one year from today.
Technical Analysis of Intra-Cellular Therapies Inc. (ITCI)
Through scrutinizing the latest numbers posted by the [Intra-Cellular Therapies Inc., ITCI], it can be observed that its last 5-days Average volume of 0.8 million was better the volume of 0.78 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 81.30% While, its Average True Range was 1.40.
Raw Stochastic average of Intra-Cellular Therapies Inc. (ITCI) in the period of the previous 100 days is set at 94.66%, which indicates a major rise in contrast to 90.14% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 27.71% that was lower than 107.92% volatility it exhibited in the past 100-days period.